{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:28Z","timestamp":1772166568572,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MEXT KAKENHI","award":["JP22K07688"],"award-info":[{"award-number":["JP22K07688"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01225-7","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T13:22:36Z","timestamp":1743513756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["3\u2032-deoxy-3\u2032-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy"],"prefix":"10.1186","volume":"15","author":[{"given":"Masayuki","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-6856","authenticated-orcid":false,"given":"Yukihiro","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akikazu","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Waseda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kiyono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiko","family":"Okazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"1225_CR1","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25:4592\u2013602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1538","journal-title":"Clin Cancer Res"},{"key":"1225_CR2","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2159-8290.CD-20-0962","volume":"11","author":"MF Sanmamed","year":"2021","unstructured":"Sanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, et al. A Burned-Out CD8\u2009+\u2009T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer Discov. 2021;11:1700\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0962","journal-title":"Cancer Discov"},{"key":"1225_CR3","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1\u2009+\u2009CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114:4993\u20138. https:\/\/doi.org\/10.1073\/pnas.1705327114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1225_CR4","doi-asserted-by":"publisher","first-page":"e003079","DOI":"10.1136\/jitc-2021-003079","volume":"9","author":"M Sato","year":"2021","unstructured":"Sato M, Umeda Y, Tsujikawa T, Mori T, Morikawa M, Anzai M, et al. Predictive value of 3\u2019-deoxy-3\u2019-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. J Immunother Cancer. 2021;9:e003079. https:\/\/doi.org\/10.1136\/jitc-2021-003079","journal-title":"J Immunother Cancer"},{"key":"1225_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology Meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"1225_CR6","doi-asserted-by":"publisher","first-page":"e000938","DOI":"10.1136\/jitc-2020-000938","volume":"8","author":"EL van der Veen","year":"2020","unstructured":"van der Veen EL, Giesen D, Pot-de Jong L, Jorritsma-Smit A, De Vries EGE. Lub-de Hooge MN. 89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs. J Immunother Cancer. 2020;8:e000938. https:\/\/doi.org\/10.1136\/jitc-2020-000938","journal-title":"J Immunother Cancer"},{"key":"1225_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13550-018-0376-6","volume":"8","author":"R Iqbal","year":"2018","unstructured":"Iqbal R, Kramer GM, Frings V, Smit EF, Hoekstra OS, Boellaard R, et al. Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. EJNMMI Res. 2018;8:22. https:\/\/doi.org\/10.1186\/s13550-018-0376-6","journal-title":"EJNMMI Res"},{"key":"1225_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.radonc.2010.10.011","volume":"98","author":"P Vera","year":"2011","unstructured":"Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with \u00b9\u2078F-fluoro-2-deoxy-d-glucose (FDG), proliferation with \u00b9\u2078F-fluoro-thymidine (FLT), and hypoxia with \u00b9\u2078fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol. 2011;98:109\u201316. https:\/\/doi.org\/10.1016\/j.radonc.2010.10.011","journal-title":"Radiother Oncol"},{"key":"1225_CR9","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1007\/s00330-019-06161-4","volume":"29","author":"Y Umeda","year":"2019","unstructured":"Umeda Y, Tsujikawa T, Anzai M, Morikawa M, Waseda Y, Kadowaki M, et al. The vertebral 3\u2032-deoxy-3\u2019-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer. Eur Radiol. 2019;29:3908\u201317. https:\/\/doi.org\/10.1007\/s00330-019-06161-4","journal-title":"Eur Radiol"},{"key":"1225_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with Tremelimumab. J Nucl Med. 2010;51:340\u20136. https:\/\/doi.org\/10.2967\/jnumed.109.070946","journal-title":"J Nucl Med"},{"key":"1225_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2967\/jnumed.113.136127","volume":"55","author":"A Leimgruber","year":"2014","unstructured":"Leimgruber A, M\u00f6ller A, Everitt SJ, Chabrot M, Ball DL, Solomon B, et al. Effect of platinum-based chemoradiotherapy on cellular proliferation in bone marrow and spleen, estimated by (18)F-FLT PET\/CT in patients with locally advanced non-small cell lung cancer. J Nucl Med. 2014;55:1075\u201380. https:\/\/doi.org\/10.2967\/jnumed.113.136127","journal-title":"J Nucl Med"},{"key":"1225_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MNM.0000000000001657","volume":"44","author":"T Zhang","year":"2023","unstructured":"Zhang T, Zhang J, Wang H, Li P. Correlations between glucose metabolism of bone marrow on 18 F-fluoro-D-glucose PET\/computed tomography and hematopoietic cell populations in autoimmune diseases. Nucl Med Commun. 2023;44:212\u20138. https:\/\/doi.org\/10.1097\/MNM.0000000000001657","journal-title":"Nucl Med Commun"},{"key":"1225_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and Platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176\u201381. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.024","journal-title":"Lung Cancer"},{"key":"1225_CR14","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1007\/s00330-016-4568-z","volume":"27","author":"JW Lee","year":"2017","unstructured":"Lee JW, Seo KH, Kim ES, Lee SM. The role of 18F-fluorodeoxyglucose uptake of bone marrow on PET\/CT in predicting clinical outcomes in non-small cell lung cancer patients treated with chemoradiotherapy. Eur Radiol. 2017;27:1912\u201321. https:\/\/doi.org\/10.1007\/s00330-016-4568-z","journal-title":"Eur Radiol"},{"key":"1225_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2018.01.020","volume":"118","author":"JW Lee","year":"2018","unstructured":"Lee JW, Choi JS, Lyu J, Lee SM. Prognostic significance of 18F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer. Lung Cancer. 2018;118:41\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.020","journal-title":"Lung Cancer"},{"key":"1225_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/MNM.0000000000001583","volume":"43","author":"M Ishibashi","year":"2022","unstructured":"Ishibashi M, Norikane T, Yamamoto Y, Imajo M, Takami Y, Mitamura K, et al. Correlation of bone marrow 2-deoxy-2-[18F]fluoro-D-glucose uptake with systemic inflammation in patients with newly diagnosed endometrial cancer. Nucl Med Commun. 2022;43:916\u201321. https:\/\/doi.org\/10.1097\/MNM.0000000000001583","journal-title":"Nucl Med Commun"},{"key":"1225_CR17","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2967\/jnumed.120.254482","volume":"62","author":"R Nakamoto","year":"2021","unstructured":"Nakamoto R, Zaba LC, Liang T, Reddy SA, Davidzon G, Aparici CM, et al. Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET\/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. J Nucl Med. 2021;62:1380\u20133. https:\/\/doi.org\/10.2967\/jnumed.120.254482","journal-title":"J Nucl Med"},{"key":"1225_CR18","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","volume":"47","author":"RD Seban","year":"2020","unstructured":"Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020;47:2301\u201312. https:\/\/doi.org\/10.1007\/s00259-020-04757-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1225_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.11.012","volume":"89","author":"M Ameratunga","year":"2018","unstructured":"Ameratunga M, Ch\u00e9nard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, et al. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1\/PD-L1 inhibitors. Eur J Cancer. 2018;89:56\u201363. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.012","journal-title":"Eur J Cancer"},{"key":"1225_CR20","doi-asserted-by":"publisher","first-page":"1506824","DOI":"10.1155\/2017\/1506824","volume":"2017","author":"M Moschetta","year":"2017","unstructured":"Moschetta M, Uccello M, Kasenda B, Mak G, McClelland A, Boussios S, et al. Dynamics of neutrophils-to-lymphocyte ratio predict outcomes of PD-1\/PD-L1 Blockade. BioMed Res Int. 2017;2017:1506824. https:\/\/doi.org\/10.1155\/2017\/1506824","journal-title":"BioMed Res Int"},{"key":"1225_CR21","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/diagnostics11091681","volume":"11","author":"C Ferrari","year":"2021","unstructured":"Ferrari C, Santo G, Merenda N, Branca A, Mammucci P, Pizzutilo P, et al. Immune checkpoint inhibitors in advanced NSCLC: [18F]FDG PET\/CT as a troubleshooter in treatment response. Diagnostics (Basel). 2021;11:1681. https:\/\/doi.org\/10.3390\/diagnostics11091681","journal-title":"Diagnostics (Basel)"},{"key":"1225_CR22","doi-asserted-by":"publisher","first-page":"e000656","DOI":"10.1136\/jitc-2020-000656","volume":"8","author":"F Seith","year":"2020","unstructured":"Seith F, Forschner A, Weide B, G\u00fcckel B, Schwartz M, Schwenck J, et al. Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET\/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer. 2020;8:e000656. https:\/\/doi.org\/10.1136\/jitc-2020-000656","journal-title":"J Immunother Cancer"},{"key":"1225_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"1225_CR24","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"1225_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3\u2009+\u2009regulatory T cell function. Science. 2008;322:271\u20135. https:\/\/doi.org\/10.1126\/science.1160062","journal-title":"Science"},{"key":"1225_CR26","doi-asserted-by":"publisher","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint Blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019;116:22699\u2013709. https:\/\/doi.org\/10.1073\/pnas.1821218116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1225_CR27","first-page":"226","volume":"45","author":"DCP Cobben","year":"2004","unstructured":"Cobben DCP, van der Laan BFAM, Maas B, Vaalburg W, Suurmeijer AJH, Hoekstra HJ, et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med. 2004;45:226\u201331.","journal-title":"J Nucl Med"},{"key":"1225_CR28","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3390\/tomography8050211","volume":"8","author":"M Mori","year":"2022","unstructured":"Mori M, Fujioka T, Ichikawa R, Inomata R, Katsuta L, Yashima Y, et al. Comparison of 18F-fluorothymidine positron emission tomography\/computed tomography and 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with breast cancer. Tomography. 2022;8:2533\u201346. https:\/\/doi.org\/10.3390\/tomography8050211","journal-title":"Tomography"},{"key":"1225_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40425-019-0516-1","volume":"7","author":"M Scarpelli","year":"2019","unstructured":"Scarpelli M, Zahm C, Perlman S, McNeel DG, Jeraj R, Liu G. FLT PET\/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer. 2019;7:23. https:\/\/doi.org\/10.1186\/s40425-019-0516-1","journal-title":"J Immunother Cancer"},{"key":"1225_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/RLU.0000000000002967","volume":"45","author":"R Yeh","year":"2020","unstructured":"Yeh R, Trager MH, Rizk EM, Finkel GG, Barker LW, Carvajal RD, et al. FLT-PET at 6 weeks predicts response assessed by CT at 12 weeks in melanoma patients treated with pembrolizumab. Clin Nucl Med. 2020;45:267\u201375. https:\/\/doi.org\/10.1097\/RLU.0000000000002967","journal-title":"Clin Nucl Med"},{"key":"1225_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdv489","volume":"27","author":"M Ilie","year":"2016","unstructured":"Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27:147\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdv489","journal-title":"Ann Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01225-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T13:22:40Z","timestamp":1743513760000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01225-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5345944\/v1","asserted-by":"object"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments, or with comparable ethical standards. This study was approved by the Research Ethics Committee of the University of Fukui (no. 20210150). The requirement for informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no potential conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}